Abstract
Background Mpox, caused by the Mpox virus, is a zoonotic disease historically endemic in Central and West Africa. The Democratic Republic of Congo (DRC) bears the highest burden, with evolving epidemiology and significant public health challenges. Understanding severity and mortality trends is critical for global control efforts.
Methods This systematic review and meta-analysis followed PRISMA guidelines to synthesize evidence on Mpox severity and mortality in the DRC from 1970 to 2024. We searched PubMed, ScienceDirect, Web of Science identifying 22 eligible studies after screening 127 records. Data on confirmed and suspected cases, severe outcomes, and deaths were extracted. Random-effects models addressed high heterogeneity (I² > 75%), and subgroup analyses examined temporal trends (pre-1980 to 2024), regional differences (Western/Central vs. Eastern DRC), and healthcare settings (community vs. hospital). Meta-regression explored sources of heterogeneity, adjusting for study year, region, method, setting and design.
Results The pooled severity rate among 3,282 confirmed cases was 42.82% (95% CI: 31.60-54.05), declining from 68.58% pre-1980 to 27.55% in 2022-2024. Western/Central regions had higher severity (46.81%) than Eastern regions (42.66%). Case fatality rates (CFRs) were 1.89% (95% CI: 1.39-2.40) for suspected cases and 4.18% (95% CI: 0.29-8.08) for confirmed cases, with Western/Central DRC again disproportionately affected (CFR: 11.37%). Community settings showed higher CFRs (6.66%) than hospitals (0.64%), underscoring healthcare access disparities. Meta-regression confirmed study year (p < 0.001), and region as significant predictors of outcomes heterogeneity (p = 0.03), with mortality declining over time but remaining elevated in resource-limited areas.
Conclusion Mpox continues to impose a substantial burden in the DRC, with high severity and mortality rates, particularly in Western/Central regions and community settings. The observed temporal decline in severity and CFRs suggests the impact of strengthened surveillance and healthcare capacity. However, regional disparities persist, driven by inequitable healthcare access and potential differences in viral clades. Targeted interventions, including vaccination in high-risk areas, community education, and mobile health units, are urgently needed. Global collaboration must address diagnostic and treatment gaps in endemic countries to prevent cross-border outbreaks.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All data source are available in the reference list.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Coauthor's names and affiliations changed.
Data Availability
All data produced in the present work are contained in the manuscript
Abbreviations
- CFR
- Case Fatality Rate
- CI
- Confidence Interval
- DRC
- Democratic Republic of Congo
- HCW
- Healthcare worker
- HIV/AIDS
- Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome
- MeSH
- Medical Subject Headings
- PCR
- Polymerase Chain Reaction
- PRISMA
- Preferred Reporting Items for Systematic Reviews and Meta-Analysis
